Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification

Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification

Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been introduced for the treatment of non-small cell lung cancer (NSCLC), the emergence of secondary T790M mutation in EGFR or amplification of the Met proto-oncogene restrain the clinical success of EGFR-TKIs. Sinc...

Full description

Bibliographic Details
Main Authors: Jang, Won-Jun, Jung, Sung-Keun, Kang, Jong-Soon, Jeong, Joo-Won, Bae, Moon-Kyoung, Joo, Sang Hoon, Park, Gyu Hwan, Kundu, Joydeb K, Hong, Young-Soo, Jeong, Chul-Ho
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462346/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462346/

Similar Items